-
EP3881842
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3881842
| EP3881842 - COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 29.07.2022 Database last updated on 19.10.2024 | |
| Former | The application has been published Status updated on 20.08.2021 | Most recent event Tooltip | 29.07.2022 | Application deemed to be withdrawn | published on 31.08.2022 [2022/35] | Applicant(s) | For all designated states Stalicla S.A. Avenue de Sécheron 15 1202 Geneva / CH | [2021/38] | Inventor(s) | 01 /
DURHAM, Lyn Avenue de Secheron 15 1202 Geneva / CH | 02 /
GUNEY, Emre World Trade Center Moll de Barcelona s/n Edif, Este Barcelona 08039 / ES | 03 /
PEREZ-CANO, Laura World Trade Center Moll de Barcelona s/n Edif, Este Barcelona 08039 / ES | 04 /
SIRCI, Francesco World Trade Center Moll de Barcelona s/n Edif, Este Barcelona 08039 / ES | [2022/11] |
| Former [2021/43] | 01 /
DURHAM, Lyn Avenue de Secheron 15 1202 Geneva / CH | ||
| Former [2021/38] | 01 /
BURHAM, Lyn Avenue de Secheron 15 1202 Geneva / CH | Representative(s) | Stolmár & Partner Intellectual Property GmbH Rue du Cendrier 15 CP 1489 1201 Genève / CH | [2021/38] | Application number, filing date | 20164331.9 | 19.03.2020 | [2021/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3881842 | Date: | 22.09.2021 | Language: | EN | [2021/38] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 14.09.2020 | Classification | IPC: | A61K31/196, A61P25/00, G01N33/50 | [2021/38] | CPC: |
A61K31/196 (EP,KR,US);
A61P25/00 (EP,KR,US);
C12Q1/6883 (KR,US);
G01N33/6896 (EP);
C12Q2600/106 (US);
C12Q2600/112 (KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/38] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON STÖRUNGEN DES AUTISMUSSPEKTRUMS | [2021/38] | English: | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | [2021/38] | French: | COMPOSITIONS POUR LE TRAITEMENT D'UN TROUBLE DU SPECTRE AUTISTIQUE | [2021/38] | Examination procedure | 23.02.2022 | Application deemed to be withdrawn, date of legal effect [2022/35] | 13.04.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2022/35] | Fees paid | Penalty fee | Additional fee for renewal fee | 31.03.2022 | 03 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]EP2523661 (INST NAT SANTE RECH MED [FR], et al) [X] 1-16 * paragraphs [0001], [0038], [0039], example *; | [X]EP3498297 (STALICLA S A [CH]) [X] 1-16 * paragraphs [0058] and [0078]-[0080] *; | [X] - BEN-ARI YEHEZKEL ED - BEN-ARI Y ET AL, "NKCC1 Chloride Importer Antagonists Attenuate Many Neurological and Psychiatric Disorders", TRENDS IN NEUROSCIENCES, (20170930), vol. 40, no. 9, doi:10.1016/J.TINS.2017.07.001, ISSN 0166-2236, pages 536 - 554, XP085163722 [X] 1-16 * page 538 * * page 541, paragraphs 1,2 * * Box 3 * DOI: http://dx.doi.org/10.1016/j.tins.2017.07.001 | [X] - GALINA SCHMUNK ET AL, "Channelopathy pathogenesis in autism spectrum disorders", FRONTIERS IN GENETICS, (20130101), vol. 4, doi:10.3389/fgene.2013.00222, XP055725085 [X] 1-16 * abstract * * page 8, column r, paragraph 2; table 3 * * page 8, column r, paragraph 3 - page 9, column l, paragraph 1 * DOI: http://dx.doi.org/10.3389/fgene.2013.00222 | by applicant | - BAIO et al., "Prevalence of Autism Spectrum Disorder Among Children Aged 8 Years - Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2014", MMWR Surveill Summ., (20180427), vol. 67, no. 6, pages 1 - 23 | - LORIO, "Transcriptional data: a new gateway to drug repositioning?", Drug Discovery Today, (20130000), vol. 18, pages 31 - 86 | - GILLBERG et al., "The ESSENCE in child psychiatry: Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations", Res Dev Disabil., (20101100), vol. 31, no. 6, pages 1543 - 51 | - HANSEN et al., "Neurodevelopmental disorders: prevalence and comorbidity in children referred to mental health services", Nord J Psychiatry, (20180500), vol. 72, no. 4, pages 285 - 291 | - LEITNER et al., "The co-occurrence of autism and attention deficit hyperactivity disorder in children - what do we know?", Front Hum Neurosci., (20140429), vol. 8, page 268 | - KUSHKI et al., "Examining overlap and homogeneity in ASD, ADHD, and OCD: a data-driven, diagnosis-agnostic approach", Transl Psychiatry, (20190000), vol. 9, page 318 | - KERN et al., "Shared Brain Connectivity Issues, Symptoms, and Comorbidities in Autism Spectrum Disorder, Attention Deficit/Hyperactivity Disorder, and Tourette Syndrome", Brain Connect., (20150800), vol. 5, no. 6, pages 321 - 35 | - MASSI et al., "An Overview of Autism Spectrum Disorder, Heterogeneity and Treatment Options", Neurosci Bull., (20170400), vol. 33, no. 2, doi:10.1007/s12264-017-0100-y, pages 183 - 193, XP036195138 DOI: http://dx.doi.org/10.1007/s12264-017-0100-y | - CHAIDEZ et al., "Gastrointestinal problems in children with autism, developmental delays or typical development", J Autism Dev Disord., (20140000), vol. 44, pages 1117 - 1127 | - ROSSIGNOL et al., "Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis", Mol Psychiatry, (20120000), vol. 17, no. 3, pages 290 - 314 | - GOINES, VAN DE WATER, "The immune system's role in the biology of autism", Curr Opin Neurol., (20100000), vol. 23, pages 111 - 117, XP009142268 | - RICCI et al., "Altered cytokine and BDNF levels in autism spectrum disorder", Neurotox Res., (20131100), vol. 24, no. 4, pages 491 - 501 | - JYONOUCHI et al., "Cytokine profiles by peripheral blood monocytes are associated with changes in behavioral symptoms following immune insults in a subset of ASD subjects: an inflammatory subtype?", J Neuroinflammation, (20141027), vol. 11, doi:10.1186/s12974-014-0187-2, page 187, XP021202889 DOI: http://dx.doi.org/10.1186/s12974-014-0187-2 | - GLADYSZ et al., "Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?", Mol Neurobiol., (20180800), vol. 55, no. 8, doi:10.1007/s12035-017-0822-x, pages 6387 - 6435, XP036552426 DOI: http://dx.doi.org/10.1007/s12035-017-0822-x | - JOBSKI et al., "Use of psychotropic drugs in patients with autism spectrum disorders: a systematic review", Acta Psychiatr Scand, (20170000), vol. 135, no. 1, pages 8 - 28 | - FUNG et al., "Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis", Pediatrics, (20160000), vol. 137, no. 2, pages S124 - 35 | - AMAN et al., "Safety and Efficacy of Memantine in Children with Autism: Randomized, Placebo-Controlled Study and Open-Label Extension", J Child Adolesc Psychopharmacol., (20170600), vol. 27, no. 5, pages 403 - 412 | - SCHADE, "D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review", Int J Neuropsychopharmacol., (20160420), vol. 19, no. 4 | - ALOLABY et al., "Molecular biomarkers predictive of sertraline treatment response in young children with fragile X syndrome", Brain Dev., (20170600), vol. 39, no. 6, pages 483 - 492 | - VEENSTRA-VANDERWEELE et al., "Arbaclofen in Children and Adolescents with Autism Spectrum Disorder: A Randomized, Controlled, Phase 2 Trial", Neuropsychopharmacology, (20170600), vol. 42, no. 7, pages 1390 - 1398 | - SINGH et al., "Sulforaphane treatment of autism spectrum disorder (ASD", PNAS, (20140000), vol. 111, no. 43, doi:10.1073/pnas.1416940111, pages 15550 - 5, XP055166974 DOI: http://dx.doi.org/10.1073/pnas.1416940111 | - LEMONIER et al., "A randomised controlled trial of bumetanide in the treatment of autism in children", Transl Psychiatry, (20120000), vol. 11, no. 2, page e202 | - LEMONIER et al., "Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders", Translational Psychiatry, (20170000), vol. 7, page e1056 | - BERNIER et al., "Disruptive CHD8 mutations define a subtype of autism early in development", Cell, (20140717), vol. 158, no. 2, pages 263 - 276 | - KUECHLER et al., "Bainbridge-Ropers syndrome caused by loss-of-function variants in ASXL3: a recognizable condition", Eur J Hum Genet., (20170200), vol. 25, no. 2, pages 183 - 191 | - SCHMUNK et al., "Channelopathy pathogenesis in autism spectrum disorders", Front Genet., (20131105), vol. 4, page 222 | - SOHYA et al., "Chronic membrane depolarization-induced morphological alteration of developing neurons", Neuroscience, (20070302), vol. 145, no. 1, doi:10.1016/j.neuroscience.2006.11.045, pages 232 - 40, XP005886496 DOI: http://dx.doi.org/10.1016/j.neuroscience.2006.11.045 | - HE, "Prolonged membrane depolarization enhances midbrain dopamine neuron differentiation via epigenetic histone modifications", Stem Cells, (20111100), vol. 29, no. 11, pages 1861 - 73 | - WEN et al., "Excitatory amino acid glutamate: role in peripheral nociceptive transduction and inflammation in experimental and clinical osteoarthritis", Osteoarthritis Cartilage, (20151100), vol. 23, no. 11, doi:10.1016/j.joca.2015.03.017, pages 2009 - 16, XP029321991 DOI: http://dx.doi.org/10.1016/j.joca.2015.03.017 | - OSIKOWICZ et al., "The glutamatergic system as a target for neuropathic pain relief", Exp Physiol., (20130200), vol. 98, no. 2, pages 372 - 84 | - SWAIM et al., "Platelets contribute to allograft rejection through glutamate receptor signaling", J Immunol., (20101201), vol. 185, no. 11, pages 6999 - 7006 | - DARAIO et al., "SNAP-25b-deficiency increases insulin secretion and changes spatiotemporal profile of Ca2+oscillations in β cell networks", Sci Rep., (20170810), vol. 7, no. 1, page 7744 | - ABEND et al., Neonatal Seizures. Volpe's Neurology of the Newborn, (20180000), pages 275 - 321 | - SOUSA-SANTOS et al., "Congenital hyperinsulinism in two siblings with ABCC8 mutation: same genotype, different phenotypes", Arch Endocrinol Metab., (20181000), vol. 62, no. 5, pages 560 - 565 | - AKA et al., "Seizures and diagnostic difficulties in hyperinsulinism-hyperammonemia syndrome", Turk J Pediatr., (20160000), vol. 58, no. 5, pages 541 - 544 | - SHANNIK et al., "Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?", Diabetes Care, (20080200), vol. 31, no. 2, pages 262 - 8 | - CHOBANIAN et al., "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure", Hypertension, (20031204), vol. 2, no. 6, pages 1206 - 52 | - FLYNN et al., "Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents", Pediatrics, (20170900), vol. 140, no. 3, page e20171904 | - VALIATHAN et al., "Reference ranges of lymphocyte subsets in healthy adults and adolescents with special mention of T cell maturation subsets in adults of South Florida", Immunobiology, (20140700), vol. 219, no. 7, doi:10.1016/j.imbio.2014.02.010, pages 487 - 96, XP028653872 DOI: http://dx.doi.org/10.1016/j.imbio.2014.02.010 | - DARENDELILER et al., "Reevaluation of growth hormone deficiency during and after growth hormone (GH) treatment: diagnostic value of GH tests and IGF-I and IGFBP-3 measurements", J Pediatr Endocrinol Metab., (20040700), vol. 17, no. 7, pages 1 007 - 12 | - SCHOPLER et al., "Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS", J Autism Dev Disord., (19800300), vol. 10, no. 1, pages 91 - 103, XP008028604 | - LORIO, "Discovery of drug mode of action and drug repositioning from transcriptional responses", Proc Natl Acad Sci USA., (20100817), vol. 107, no. 33, doi:10.1073/pnas.1000138107, pages 14621 - 6, XP055057022 DOI: http://dx.doi.org/10.1073/pnas.1000138107 | - CARRELLA D et al., "Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis", Bioinformatics, (20140000), vol. 30, no. 12, pages 1787 - 1788 | - SIRCI, "Computational Drug Networks: a computational approach to elucidate drug mode of action and to facilitate drug repositioning for neurodegenerative diseases", Drug Discovery Today: Disease Model, (20160000), vol. 19, pages 11 - 17 | - PUSHPAKOM, "Drug repurposing: progress, challenges and recommendations", Nature reviews Drug discovery, (20190000), vol. 18, no. 1, pages 41 - 58 | - MANSVELDER et al., "The relation of exocytosis and rapid endocytosis to calcium entry evoked by short repetitive depolarizing pulses in rat melanotropic cells", J Neurosci., (19980101), vol. 18, no. 1, pages 81 - 92 | - MANSVELDER et al., "All classes of calcium channel couple with equal efficiency to exocytosis in rat melanotropes, inducing linear stimulus-secretion coupling", J Physiol., (20000715), vol. 526, no. 2, pages 327 - 39 | EP20180204763 |